Heron Therapeutics | HRTX - Current Assets


Heron Therapeutics reported $229.84M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
ALKERMES USD 1.58B 57.83M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amarin USD 612.88M 10.12M Sep/2026
ANI Pharmaceuticals USD 902.82M 77.39M Sep/2026
Anika Therapeutics USD 99.19M 5.63M Jun/2026
Arrowhead Research USD 1.67B 168.34M Jun/2026
Eisai JPY 883.01B 121.38B Jun/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Heron Therapeutics USD 229.84M 861K Jun/2026
Insmed USD 1.71B 72.59M Sep/2026
Ligand Pharmaceuticals USD 608.23M 848.88M Sep/2026
Merck USD 38.94B 2.26B Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 10.3B 9.68B Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Veracyte USD 467.88M 106.9M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026